[1] |
Subramanian, S., Ekbom, A. and Rhodes, J.M. (2017) Recent Advances in Clinical Practice: A Systematic Review of Isolated Colonic Crohn’s Disease: The Third IBD? Gut, 66, 362-381. https://doi.org/10.1136/gutjnl-2016-312673 |
[2] |
Vande Casteele, N., Khanna, R., Levesque, B.G., Stitt, L., Zou, G.Y., Singh, S., Lockton, S., Hauenstein, S., Ohrmund, L., Greenberg, G.R., et al. (2015) The Relationship between Infliximab Concentrations, Antibodies to Infliximab and Disease Activity in Crohn’s Disease. Gut, 64, 1539-1545. https://doi.org/10.1136/gutjnl-2014-307883 |
[3] |
Yarur, A.J., Kanagala, V., Stein, D.J., Czul, F., Quintero, M.A., Agrawal, D., Patel, A., Best, K., Fox, C., Idstein, K., et al. (2017) Higher Infliximab trough Levels Are Associated with Perianal Fistula Healing in Patients with Crohn’s Disease. Alimentary Pharmacology & Therapeutics, 45, 933-940. https://doi.org/10.1111/apt.13970 |
[4] |
Lichtenstein, L., Ron, Y., Kivity, S., Ben-Horin, S., Israeli, E., Fraser, G.M., Dotan, I., Chowers, Y., Confino-Cohen, R. and Weiss, B. (2015) Infliximab-Related Infusion Reactions: Systematic Review. Journal of Crohn’s & Colitis, 9, 806-815. https://doi.org/10.1093/ecco-jcc/jjv096 |
[5] |
Steenholdt, C., Svenson, M., Bendtzen, K., Thomsen, O.O., Brynskov, J. and Ainsworth, M.A. (2012) Acute and Delayed Hypersensitivity Reactions to Infliximab and Adalimumab in a Patient with Crohn’s Disease. Journal of Crohn’s & Colitis, 6, 108-111. https://doi.org/10.1016/j.crohns.2011.08.001 |
[6] |
Balint, A., Rutka, M., Vegh, Z., Kurti, Z., Gecse, K.B., Banai, J., Bene, L., Gasztonyi, B., Kristof, T., Lakatos, L., et al. (2017) Frequency and Characteristics of Infusion Reactions during Biosimilar Infliximab Treatment in Inflammatory Bowel Diseases: Results from Central European Nationwide Cohort. Expert Opinion on Drug Safety, 16, 885-890. https://doi.org/10.1080/14740338.2017.1323330 |
[7] |
Li, N. and Shi, R.H. (2018) Updated Review on Immune Factors in Pathogenesis of Crohn’s Disease. World Journal of Gastroenterology, 24, 15-22. https://doi.org/10.3748/wjg.v24.i1.15 |
[8] |
Toedter, G.P., Blank, M., Lang, Y., Chen, D., Sandborn, W.J. and de Villiers, W.J. (2009) Relationship of C-Reactive Protein with Clinical Response after Therapy with Ustekinumab in Crohn’s Disease. The American Journal of Gastroenterology, 104, 2768-2773. https://doi.org/10.1038/ajg.2009.454 |
[9] |
Babouri, A., Roblin, X., Filippi, J., Hebuterne, X., Bigard, M.A. and Peyrin-Biroulet, L. (2014) Tolerability of One Hour 10 mg/kg Infliximab Infusions in Inflammatory Bowel Diseases: A Prospective Multicenter Cohort Study. Journal of Crohn’s & Colitis, 8, 161-165. https://doi.org/10.1016/j.crohns.2013.08.004 |
[10] |
Baert, F., Drobne, D., Gils, A., Vande Casteele, N., Hauenstein, S., Singh, S., Lockton, S., Rutgeerts, P. and Vermeire, S. (2014) Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association, 12, 1474-1481. https://doi.org/10.1016/j.cgh.2014.01.033 |
[11] |
Thompson, M.P., Fanaroff, A.C., Parker, J.D., Vallabhajosyula, S. and Sterling, M.R. (2018) Focusing on the Future of Cardiovascular Outcomes Research: Highlights from the American Heart Association/American Stroke Association Quality of Care and Outcomes Research 2018 Scientific Sessions. Circulation Cardiovascular Quality and Outcomes, 11, e004871. https://doi.org/10.1161/circoutcomes.118.004871 |
[12] |
Chung, E.S., Packer, M., Lo, K.H., Fasanmade, A.A. and Willerson, J.T. (2003) Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-Alpha, in Patients with Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy against Congestive Heart Failure (ATTACH) Trial. Circulation, 107, 3133-3140. https://doi.org/10.1161/01.cir.0000077913.60364.d2 |
[13] |
Zhou, Y., He, H., Wang, P., Zhang, T., Lin, M., Wang, H., Nie, Y. and Chen, Y. (2015) Infliximab for the Treatment of Crohn’s Disease: Efficacy and Safety in a Chinese Single-Center Retrospective Study. European Journal of Gastroenterology & Hepatology, 27, 1270-1275. https://doi.org/10.1097/meg.0000000000000447 |
[14] |
Li, W., Xu, J., Zhao, J. and Zhang, R. (2017) Oxaliplatin and Infliximab Combination Synergizes in Inducing Colon Cancer Regression. Medical Science Monitor, 23, 780-789. https://doi.org/10.12659/MSM.901880 |
[15] |
李罗红, 骆欧, 唐莉, 张铭光. 英夫利西单抗治疗克罗恩病的输注护理管理体会[J]. 华西医学, 2013, 28(8): 1247-1249. https://doi.org/10.7507/1002-0179.20130391 |
[16] |
袁虞芳. 注射用英夫利西单抗治疗克罗恩病的疗效及护理体会[J]. 中国继续医学教育, 2018, 10(13): 147-149. https://doi.org/10.3969/j.issn.1674-9308.2018.13.079 |
[17] |
Mazzuoli, S., Tricarico, D., Demma, F., Furneri, G. and Guglielmi, F.W. (2016) Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients’ Sat-isfaction and Cost Analysis. A Cohort Study in IBD Patients. PLoS ONE, 11, e0166443. https://doi.org/10.1371/journal.pone.0166443 |